Archived Monthly Oncology Tumor Boards: Treatment of Patients with Bladder and Upper Tract Urothelial Cancer

Archived Monthly Oncology Tumor Boards: Treatment of Patients with Bladder and Upper Tract Urothelial Cancer is organized by National Comprehensive Cancer Network (NCCN) and will be held from Oct 06, 2022 - Oct 06, 2023.,,Description:,The recent approvals of nivolumab for adjuvant treatment of urothelial carcinoma who are at high risk of recurrence following radical resection and the antibody-drug conjugates enfortumab vedotin-ejfv and sacituzumab govitecan-hziy for previously treated metastatic urothelial cancer represent substantial updates to the treatment of urothelial bladder and upper tract tumors. Clinicians can find it difficult to stay current on these updates. Education on the appropriate use of these therapies and considerations for treatment planning and side effect management can benefit clinicians interested in incorporating these therapies into their clinical practice.,,Learning Objectives:,Following this activity, participants should be able to:,• Discuss the results of recent clinical trials for the treatment of non-muscle invasive bladder cancer and their potential impact on the treatment of BCG-unresponsive disease.,• Describe new and emerging systemic therapy options for patients with muscle-invasive or metastatic urothelial bladder cancer and how patient and disease characteristics can guide therapy choice.,•Review how antibody-drug conjugates may be incorporated into treatment planning for previously treated metastatic urothelial carcinoma.,,Additional details will be posted as soon as information is available.